For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

For the past 10 years, medications and inhalers began to help less and less with Rose Walsh’s breathing problems. Battling ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Synairgen plc (LON:SNG – Get Free Report)’s share price shot up 33.3% during trading on Monday . The company traded as high as GBX 3 ($0.04) and last traded at GBX 3 ($0.04). 205,983 shares changed ...

Making America Healthy Again’ is a complicated, messy, and massive undertaking bound to meet resistance. Reducing nicotine in ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Liquidia (NASDAQ:LQDA – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report ...